title: Gastric cancer drug trials - are women second class citizens?
authors.affiliation: Department of Orthopaedic Surgery, Campbell Clinic and Pathology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
authors.forename: Lishi
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Orthopaedic Surgery, Campbell Clinic and Pathology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Jiao
authors.affiliation: Department of Neuroscience, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
authors.forename: Yun
authors.initials: Y
authors.lastname: Jiao
authors.affiliation: Center for Endemic Disease Control, Centers for Disease Control and Prevention, Harbin Medical University, Harbin, Heilongjiang 150081, PR China.
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Department of Orthopaedic Surgery, Campbell Clinic and Pathology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
authors.forename: Weikuan
authors.initials: W
authors.lastname: Gu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D040301:Vascular Endothelial Growth Factor Receptor-2